查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984059

下一代腫瘤治療設備和解決方案市場：按設備類型、技術、癌症類型和最終用戶分類－2026-2032年全球市場預測

Next-Generation Oncology Devices & Solutions Market by Device Type, Technology, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，下一代腫瘤設備和解決方案市場價值將達到 230.5 億美元，到 2026 年將成長至 280.2 億美元，到 2032 年將達到 911.8 億美元，複合年成長率為 21.70%。

主要市場統計數據
基準年 2025 230.5億美元
預計年份：2026年 280.2億美元
預測年份 2032 911.8億美元
複合年成長率 (%) 21.70%

腫瘤醫療設備及解決方案市場正邁入一個以技術融合、臨床精準和持續推進以病人為中心的工作流程為特徵的新時代。分子診斷、影像學和醫療設備自動化技術的進步正推動腫瘤治療從間歇性干預轉向持續的、數據驅動的管理。因此，臨床路徑正在重組，以將早期檢測、更精準的腫瘤表徵和適應性治療納入常規實踐。這種變革並非局限於單一技術領域，而是涵蓋診斷、影像、監測、手術和治療性醫療設備等各個方面，所有這些技術協同運作，共同建構封閉回路型腫瘤治療系統。

從概念驗證(PoC) 過渡到廣泛的臨床部署，需要製造、監管策略、報銷途徑和醫療採購結構等方面的協調一致。相關人員必須應對日益成長的臨床證據期望、與醫療資訊科技系統的互通性以及與醫療團隊的無縫整合等挑戰。因此，最成功的機構將是那些能夠將嚴格的臨床檢驗、切實可行的商業化計劃、對醫療服務提供者工作流程的深刻洞察以及向支付方和醫療系統展示實際價值的能力結合起來的機構。

新興的人工智慧、基因組學、影像技術和微創技術如何融合，重新定義腫瘤治療的臨床路徑和經營模式。

臨床實踐的根本性轉變、技術的成熟以及策略市場趨勢正在加速整個腫瘤醫療設備生態系統的轉型。人工智慧和先進的分析技術不再是小眾功能，而是能夠提高診斷成像準確性、簡化病理工作流程以及在治療方法選擇中優先考慮基因組分析結果的實用工具。同時，次世代定序和數位病理正在縮短診斷時間，並支持多模態數據的整合，從而幫助精準醫療。

評估關稅政策變化對全球供應鏈、醫療設備設計、監管合規性和癌症治療技術整體趨勢的策略性影響。

美國2025年實施的關稅措施為腫瘤醫療設備及解決方案領域的企業帶來了新的營運和策略考量。在製造層面，進口零件和組件成本的增加影響了成本結構，促使企業重新評估全球籌資策略。許多製造商正在探索近岸外包、雙重採購和本地化供應商網路等策略，以降低關稅帶來的成本波動風險。因此，供應鏈設計正從單純的成本最佳化轉向以韌性為中心的模式，強調時間把控、庫存策略和合約柔軟性。

透過對醫療設備、技術、癌症類型和最終用戶細分進行詳細分析，我們將揭示整個腫瘤護理領域不同的發展重點和採用趨勢。

精準理解細分市場對於探索腫瘤醫療設備的產品開發重點和商業化路徑至關重要。醫療設備的分類包括診斷系統（如免疫組織化學和螢光雜合反應(FISH)）、分子平台（如聚合酵素鏈鎖反應(PCR)，包括數位 PCR 和定量 PCR）以及次世代定序(NGS)（涵蓋EXOME序、標靶基因組定序和全基因組定序）。影像技術涵蓋了從錐狀射束和多切面配置的電腦斷層掃描 (CT) 平台到 1.5T 和 3T 磁場強度的磁振造影(MRI) 系統，以及正子斷層掃描 (PET) 解決方案（PET/CT 或 PET/MRI 混合型）。超音波診斷設備從傳統的2D成像到先進的3D和四維成像功能不等，而 X 光系統則包括電腦放射成像 (CR)數位放射線(DR)。監測解決方案擴大利用生物感測器和穿戴式裝置來實現時間序列資料收集。同時，外科手術工具包括冷凍手術、腹腔鏡手術技術和機器人平台，以支援精準手術。治療設備產品組合涵蓋藥物傳輸系統和放射治療方式，其中放射治療解決方案包括近距離放射系統、線性加速器和質子治療設備。

區域比較分析揭示了法律規範、臨床基礎設施和製造地如何影響腫瘤設備的引進和市場發展。

區域趨勢對腫瘤醫療設備和解決方案的監管預期、部署計畫和商業化路徑有顯著影響。在美洲，整體的臨床試驗基礎設施、眾多專業癌症中心以及日益重視臨床和經濟價值證據的支付方環境，正在加速創新診斷和醫療設備的普及應用。該地區也是醫療設備製造和風險投資的中心，這不僅支持了快速的商業化週期，也對強力的上市後監測和真實世界數據（RWE）的生成提出了更高的要求。

現有平台、專業創新者和策略合作夥伴正在透過整合解決方案、智慧財產權定位和服務主導的差異化重新定義競爭格局。

腫瘤領域醫療設備和解決方案的競爭格局呈現出多元化的特點，既有大規模平台供應商，也有專注於臨床創新、技術領先的Start-Ups公司。成熟的醫療科技公司正利用其廣泛的銷售管道、服務網路和監管經驗，拓展硬體、軟體和服務相結合的整合解決方案。同時，一些專注於特定領域的公司在分子診斷、數位病理學和機器人等領域不斷湧現顛覆性技術，迫使成熟公司尋求夥伴關係、授權協議或進行有針對性的收購，以保持其臨床競爭力。

為高階主管提供可操作的策略挑戰，以加強供應鏈、證據產生、產品模組化和經營模式，從而確保永續的競爭優勢。

產業領導企業必須採取多管齊下的策略來降低系統性風險，同時抓住下一代腫瘤醫療設備所帶來的機會。首先，供應鏈韌性應成為一項策略重點。供應商多元化、盡可能投資近岸製造以及重新設計產品以適應組件的柔軟性，都能降低政策引發的干擾風險。同時，企業應優先產生符合支付方要求和醫療採購標準的可靠臨床和衛生經濟學證據。儘早與臨床醫生、衛生技術評估機構和支付方決策者合作，將有助於試驗設計和資料收集更精準地聚焦於最相關的終點指標。

透過結合專家訪談、監管和臨床證據審查以及多方面的資訊匹配，我們確保獲得可靠且可操作的見解。

本分析所依據的研究採用了一種多層次的調查方法，旨在確保研究的嚴謹性、多方驗證以及與相關人員的相關性。主要研究包括對意見領袖、採購負責人、監管專家以及醫療設備製造商和醫院系統的管理人員進行結構化訪談。此外，還透過系統性地查閱公開的監管文件、臨床試驗註冊資訊、同行評審文獻和專利資訊披露，補充了這些定性資訊，以識別技術進步和證據缺口。同時，透過分析公司新聞稿、產品公告和投資者報告，檢驗了市場和技術趨勢，以了解策略意圖和資源分配。

摘要重點強調綜合臨床平台、實證商業化以及對政策和區域差異的適應能力。

總而言之，下一代腫瘤醫療設備和解決方案將由整合高精度診斷、先進影像、智慧軟體和微創治療的平台定義，並最終形成一致的臨床路徑。能夠將卓越的工程技術與臨床證據、監管前瞻性和靈活的商業模式相結合的機構將取得成功。關稅政策的變化、區域監管差異以及支付方期望的改變等外部因素將繼續影響策略選擇，並進一步凸顯對適應性價值鍊和基於價值的定價方法的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 下一代腫瘤治療設備和解決方案市場：按設備類型分類

  • 診斷設備
    • 螢光原位雜合反應
    • 免疫組織化學
    • 次世代定序
      • EXOME定序
      • 目標面板
      • 全基因測序
    • 聚合酵素鏈鎖反應
      • 數位PCR
      • 定量PCR
  • 醫療影像設備
    • 電腦斷層掃描
      • 錐狀射束CT
      • 多切面CT
    • 磁振造影
      • 1.5T 影像診斷
      • 3T成像
    • 正子斷層掃描
      • PET/CT混合
      • PET/MRI混合
    • 超音波影像
      • 2D成像
      • 3D/4D成像
    • X光影像診斷
      • 電腦放射成像
      • 數位放射線攝影
  • 監控設備
    • 生物感測器
    • 穿戴式裝置
  • 手術器械
    • 冷凍手術
    • 腹腔鏡手術
    • 機器人手術
  • 治療設備
    • 藥物輸送裝置
    • 放射治療設備
      • 近距離放射治療系統
      • 直線加速器
      • 質子束治療系統

第9章 下一代腫瘤設備和解決方案市場：按技術分類

  • 人工智慧
    • 數據分析
    • 深度學習
    • 機器學習
  • 生物資訊學
    • NGS數據分析
    • 蛋白質體學數據分析
  • 數位病理學
    • 影像分析軟體
    • 全幻燈片成像
  • 奈米科技
    • 奈米載體
    • 奈米診斷
  • 機器人技術
    • 切片檢查機器人
    • 手術機器人

第10章 按癌症類型分類的下一代腫瘤設備和解決方案市場

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第11章 下一代腫瘤設備和解決方案市場：按最終用戶分類

  • 門診部
  • 診斷檢查室
  • 醫院
  • 研究機構

第12章 下一代腫瘤設備和解決方案市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 下一代腫瘤設備和解決方案市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 下一代腫瘤設備和解決方案市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國下一代腫瘤設備與解決方案市場

第16章：中國下一代腫瘤設備與解決方案市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Brainlab
  • Danaher Corporation
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Guardant Health Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • Novartis AG
  • Paige.AI, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Royal Philips
  • Siemens AG
  • Sysmex Corporation
  • Takara Bio USA, Inc.
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-2E76C3E47F6D

The Next-Generation Oncology Devices & Solutions Market was valued at USD 23.05 billion in 2025 and is projected to grow to USD 28.02 billion in 2026, with a CAGR of 21.70%, reaching USD 91.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.05 billion
Estimated Year [2026] USD 28.02 billion
Forecast Year [2032] USD 91.18 billion
CAGR (%) 21.70%

The oncology devices and solutions landscape is entering an era defined by technological convergence, clinical precision, and a relentless drive toward patient-centered workflows. Advances in molecular diagnostics, imaging modalities, and device automation are moving oncology care from episodic intervention toward continuous, data-driven management. As a result, clinical pathways are being reconfigured to embed earlier detection, more accurate tumor characterization, and adaptive therapeutic delivery in routine practice. This evolution is not limited to a single technology class; instead, it spans diagnostic, imaging, monitoring, surgical, and therapeutic devices that together enable closed-loop oncologic care.

Transitioning from proof of concept to widespread clinical adoption requires alignment across manufacturing, regulatory strategy, reimbursement pathways, and institutional procurement. Stakeholders must navigate heightened expectations for clinical evidence, interoperability with health IT systems, and seamless integration into care teams. Consequently, the most successful organizations will be those that combine rigorous clinical validation with pragmatic commercialization plans, an acute sensitivity to provider workflows, and an ability to demonstrate real-world value to payers and health systems.

How emerging AI, genomics, imaging, and minimally invasive technologies are converging to redefine clinical pathways and commercial models in oncology care

Fundamental shifts in clinical practice, technology maturation, and strategic market behavior are collectively accelerating transformation across the oncology device ecosystem. Artificial intelligence and advanced analytics are no longer niche capabilities; they are operational tools that enhance image interpretation, streamline pathology workflows, and prioritize genomic findings for treatment selection. Concurrently, next-generation sequencing and digital pathology are reducing diagnostic turnaround times and enabling multi-modal data synthesis that supports precision medicine.

In parallel, imaging systems have evolved to offer higher resolution, hybrid modalities, and quantitative biomarkers that improve lesion characterization and response assessment. Wearable biosensors and continuous monitoring platforms are transforming patient engagement and enabling remote assessment of therapy tolerability. Surgical robotics and minimally invasive techniques are refining procedural accuracy while reducing recovery time. Taken together, these shifts are changing how oncology care is delivered, financed, and measured, with implications for clinical workflows, capital allocation, and the competitive landscape.

Assessing the strategic consequences of tariff policy shifts on global supply chains, device design, regulatory compliance, and pricing dynamics across oncology technologies

The implementation of United States tariffs in 2025 has introduced a new set of operational and strategic considerations for companies involved in oncology devices and solutions. At the manufacturing level, cost structures have been affected by increased expenses for imported components and subassemblies, which in turn has encouraged a reassessment of global sourcing strategies. Many manufacturers are evaluating nearshoring, dual-sourcing, and localized supplier networks to mitigate exposure to tariff-driven cost volatility. As a consequence, supply chain design has shifted from a pure cost-optimization focus to a resilience-centric model that emphasizes timing, inventory strategies, and contractual flexibility.

Beyond procurement, tariffs have accelerated redesign efforts for device architecture and bill-of-material simplification. Engineering teams are seeking modular designs that reduce reliance on tariff-sensitive components and prioritize standardized interfaces to enable alternative sourcing. Regulatory affairs and quality teams are also adapting, as component substitutions and supplier changes require timely documentation and revalidation to maintain compliance. On the commercial front, pricing negotiations with health systems and group purchasing organizations have become more complex, with manufacturers needing to substantiate cost increases through transparent total cost of ownership narratives and value-based contracting approaches. Finally, investors and corporate strategists are reassessing capex plans and M&A activity to capture supply chain efficiencies, secure intellectual property, and shore up manufacturing footprints in jurisdictions that reduce tariff exposure.

Unpacking device, technology, cancer type, and end user segmentation to reveal differentiated development priorities and adoption dynamics across oncology care

A nuanced understanding of segmentation is essential to navigate product development priorities and commercialization pathways across oncology devices. Device classifications span diagnostic systems such as immunohistochemistry and fluorescence in situ hybridization, molecular platforms including polymerase chain reaction with digital and quantitative PCR formats, and next-generation sequencing which itself encompasses exome sequencing, targeted panels, and whole genome sequencing approaches. Imaging technologies range from computed tomography platforms with cone beam and multi-slice configurations to magnetic resonance imaging systems offered in 1.5T and 3T field strengths, alongside positron emission tomography solutions available as PET/CT and PET/MRI hybrids. Ultrasound offerings vary from conventional two-dimensional imaging to advanced three-dimensional and four-dimensional capabilities, while X-ray systems exist in computed radiography and digital radiography forms. Monitoring solutions increasingly incorporate biosensors and wearable devices to enable longitudinal data capture, whereas surgical tools include cryosurgery, laparoscopic techniques, and robotic platforms that support precision interventions. Therapeutic device portfolios cover drug delivery systems and radiation therapy modalities, with radiation solutions spanning brachytherapy systems, linear accelerators, and proton therapy installations.

Technology-driven segmentation further clarifies adoption pathways and investment focus. Artificial intelligence is being applied through data analytics, deep learning, and machine learning to enhance diagnostic yield and operational efficiency. Bioinformatics capabilities are centered on next-generation sequencing data analysis and proteomics pipelines, while digital pathology investments emphasize image analysis software and whole slide imaging platforms. Nanotechnology development includes nanocarriers for targeted delivery and nanodiagnostics to improve sensitivity, and robotics continues to differentiate into biopsy-specific systems and surgical robotics optimized for oncology workflows. Clinical focus across cancer types-such as breast, colorectal, lung, and prostate cancers-affects diagnostic and therapeutic priorities, and end-user segmentation encompassing ambulatory care centers, diagnostic laboratories, hospitals, and research institutes determines procurement cycles, IT integration needs, and evidence requirements for adoption. Synthesizing these layers of segmentation enables product teams and commercial leaders to target feature sets, clinical validation plans, and service models that align with distinct clinical and institutional buyer needs.

Comparative regional analysis revealing how regulatory frameworks, clinical infrastructure, and manufacturing footprints influence oncology device adoption and market pathways

Regional dynamics exert a powerful influence on regulatory expectations, adoption timelines, and commercialization pathways across oncology devices and solutions. In the Americas, strong clinical trial infrastructure, a concentration of specialized cancer centers, and payer environments that increasingly reward evidence of clinical and economic value combine to accelerate uptake of innovative diagnostics and devices. This region also remains a focal point for device manufacturing and venture investment, which supports rapid commercialization cycles while demanding robust post-market surveillance and real-world evidence generation.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization initiatives coexist with country-specific reimbursement processes and procurement behaviors. In some markets, centralized approvals and value-based procurement mechanisms encourage cross-border adoption, whereas resource constraints in other jurisdictions necessitate cost-effective, scalable solutions. The region's complex reimbursement tapestry and diverse clinical practice patterns place a premium on modular product models and flexible commercial strategies. Asia-Pacific exhibits a blend of high-volume markets with fast technology adoption, alongside growing local manufacturing capability and strategic public investments in precision medicine. Regulatory authorities in key Asia-Pacific markets are increasingly receptive to expedited pathways for devices demonstrating strong clinical utility, and regional manufacturers are becoming competitive suppliers for global supply chains. Across all regions, adoption is shaped by local workforce capacity, digital infrastructure maturity, and national policy priorities that support early detection, patient access, and cancer research.

How incumbent platforms, focused innovators, and strategic collaborations are redefining competition through integrated solutions, IP positioning, and service-driven differentiation

The competitive landscape in oncology devices and solutions is defined by a mix of large platform providers, specialized technology companies, and agile startups that bring focused innovations to clinical practice. Established medical technology firms leverage broad commercial channels, service networks, and regulatory experience to scale integrated solutions that combine hardware, software, and servicing. Meanwhile, niche companies often advance disruptive capabilities in areas such as molecular diagnostics, digital pathology, and robotics, forcing incumbents to pursue partnerships, licensing agreements, or targeted acquisitions to retain clinical relevance.

Strategic collaborations between device manufacturers, software companies, and clinical research organizations are increasingly common as firms seek to assemble end-to-end value propositions. Intellectual property portfolios centering on algorithms, device interfaces, and component designs serve as key differentiators, while manufacturing scale and supplier relationships underpin cost competitiveness. Moreover, a growing number of companies are expanding offerings beyond product delivery to include data services, clinical decision support, and lifecycle management, thereby creating recurring revenue streams and deeper customer engagement. For commercial teams, understanding competitor positioning across evidence generation, reimbursement support, and aftermarket services is critical to crafting winning value propositions.

Actionable strategic imperatives for executives to strengthen supply chains, evidence generation, product modularity, and commercial models to secure lasting competitive advantage

Industry leaders must adopt a multi-dimensional approach to capture the opportunities presented by next-generation oncology devices while mitigating systemic risks. First, supply chain resilience should be elevated to strategic priority status; diversifying suppliers, investing in near-shore manufacturing where feasible, and redesigning products for component flexibility will reduce exposure to policy-driven disruptions. Simultaneously, companies should prioritize the generation of robust clinical and health economic evidence that aligns with payer requirements and institutional procurement criteria. Early engagement with clinicians, health technology assessment bodies, and payer decision-makers ensures that trial designs and data collection address the most relevant endpoints.

Product strategy should emphasize interoperability, modularity, and software-enabled upgrade paths to extend product lifecycles and support incremental feature deployment. Commercial teams need to craft pricing and contracting models that align provider incentives, including outcomes-based agreements where appropriate, and to build commercial capabilities that support complex sales cycles within hospitals and research institutes. Investing in post-market data capture and real-world evidence platforms not only strengthens regulatory and reimbursement dossiers but also supplies actionable insights for iterative product improvement. Finally, organizational priorities should include talent strategies that attract clinical, regulatory, and digital expertise, and a culture that values rapid evidence-driven iteration to keep pace with clinical innovation.

Methodological framework combining expert interviews, regulatory and clinical evidence review, and multi-source triangulation to ensure robust and actionable insights

The research underpinning this analysis relied on a layered methodology intended to ensure rigor, triangulation, and relevance to stakeholders. Primary research included structured interviews with clinical opinion leaders, procurement professionals, regulatory experts, and senior executives across device manufacturers and hospital systems. These qualitative inputs were complemented by a systematic review of publicly available regulatory filings, clinical trial registries, peer-reviewed literature, and patent disclosures to identify technology trajectories and evidence gaps. Market and technology signals were further validated through analysis of company press releases, product launch materials, and investor presentations to capture strategic intent and resource allocation.

Quantitative analysis was supported by dataset integration and cross-validation routines to ensure consistency across sources. Where appropriate, sensitivity analyses and scenario testing were used to explore implications under different regulatory or policy environments. Throughout the process, quality controls included methodological rubrics for source weighting, peer review by domain experts, and ethical safeguards to protect interview confidentiality. Limitations of the research were acknowledged and addressed by seeking diverse viewpoints across geographies, technology maturity levels, and institutional contexts, ensuring that conclusions are robust and actionable for decision-makers.

Concluding synthesis emphasizing integrated clinical platforms, evidence-driven commercialization, and resilience in the face of policy and regional variability

In summary, the next wave of oncology devices and solutions will be defined by platforms that integrate high-fidelity diagnostics, advanced imaging, intelligent software, and minimally invasive therapeutics into coherent clinical pathways. Success will favor organizations that can harmonize engineering excellence with clinical evidence, regulatory foresight, and flexible commercial models. External forces such as tariff policy shifts, regional regulatory variability, and evolving payer expectations will continue to shape strategic choices, reinforcing the need for adaptable supply chains and value-based pricing approaches.

Stakeholders that proactively align product strategies with clinical workflows, invest in real-world evidence generation, and cultivate partnerships across the ecosystem will be best positioned to accelerate adoption and realize the promise of precision oncology. Conversely, firms that maintain siloed development, under-invest in post-market data, or fail to anticipate policy-driven cost pressures risk slower uptake and margin compression. The path forward requires disciplined execution, cross-functional coordination, and a relentless focus on demonstrating tangible clinical and economic value to patients, providers, and payers alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Oncology Devices & Solutions Market, by Device Type

  • 8.1. Diagnostic Devices
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Immunohistochemistry
    • 8.1.3. Next Generation Sequencing
      • 8.1.3.1. Exome Sequencing
      • 8.1.3.2. Targeted Panels
      • 8.1.3.3. Whole Genome Sequencing
    • 8.1.4. Polymerase Chain Reaction
      • 8.1.4.1. Digital PCR
      • 8.1.4.2. Quantitative PCR
  • 8.2. Imaging Devices
    • 8.2.1. Computed Tomography
      • 8.2.1.1. Cone Beam CT
      • 8.2.1.2. Multi-Slice CT
    • 8.2.2. Magnetic Resonance Imaging
      • 8.2.2.1. 1.5T Imaging
      • 8.2.2.2. 3T Imaging
    • 8.2.3. Positron Emission Tomography
      • 8.2.3.1. PET/CT Hybrid
      • 8.2.3.2. PET/MRI Hybrid
    • 8.2.4. Ultrasound Imaging
      • 8.2.4.1. 2D Imaging
      • 8.2.4.2. 3D/4D Imaging
    • 8.2.5. X-Ray Imaging
      • 8.2.5.1. Computed Radiography
      • 8.2.5.2. Digital Radiography
  • 8.3. Monitoring Devices
    • 8.3.1. Biosensors
    • 8.3.2. Wearable Devices
  • 8.4. Surgical Devices
    • 8.4.1. Cryosurgery
    • 8.4.2. Laparoscopic Surgery
    • 8.4.3. Robotic Surgery
  • 8.5. Therapeutic Devices
    • 8.5.1. Drug Delivery Devices
    • 8.5.2. Radiation Therapy Devices
      • 8.5.2.1. Brachytherapy Systems
      • 8.5.2.2. Linear Accelerators
      • 8.5.2.3. Proton Therapy Systems

9. Next-Generation Oncology Devices & Solutions Market, by Technology

  • 9.1. Artificial Intelligence
    • 9.1.1. Data Analytics
    • 9.1.2. Deep Learning
    • 9.1.3. Machine Learning
  • 9.2. Bioinformatics
    • 9.2.1. NGS Data Analysis
    • 9.2.2. Proteomics Data Analysis
  • 9.3. Digital Pathology
    • 9.3.1. Image Analysis Software
    • 9.3.2. Whole Slide Imaging
  • 9.4. Nanotechnology
    • 9.4.1. Nanocarriers
    • 9.4.2. Nanodiagnostics
  • 9.5. Robotics
    • 9.5.1. Biopsy Robotics
    • 9.5.2. Surgical Robotics

10. Next-Generation Oncology Devices & Solutions Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. Next-Generation Oncology Devices & Solutions Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Next-Generation Oncology Devices & Solutions Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Next-Generation Oncology Devices & Solutions Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Next-Generation Oncology Devices & Solutions Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Next-Generation Oncology Devices & Solutions Market

16. China Next-Generation Oncology Devices & Solutions Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Brainlab
  • 17.9. Danaher Corporation
  • 17.10. Exact Sciences Corp.
  • 17.11. F. Hoffmann-La Roche Ltd.
  • 17.12. GE HealthCare Technologies, Inc.
  • 17.13. Guardant Health Inc.
  • 17.14. Hologic, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Johnson & Johnson Services Inc.
  • 17.17. Merck & Co., Inc.
  • 17.18. Myriad Genetics, Inc.
  • 17.19. NanoString Technologies, Inc.
  • 17.20. Natera, Inc.
  • 17.21. NeoGenomics, Inc.
  • 17.22. Novartis AG
  • 17.23. Paige.AI, Inc.
  • 17.24. PerkinElmer, Inc.
  • 17.25. QIAGEN N.V.
  • 17.26. Quest Diagnostics Incorporated
  • 17.27. Royal Philips
  • 17.28. Siemens AG
  • 17.29. Sysmex Corporation
  • 17.30. Takara Bio USA, Inc.
  • 17.31. Thermo Fisher Scientific Inc.
  • 17.32. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LINEAR ACCELERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LINEAR ACCELERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LINEAR ACCELERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DATA ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DATA ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DATA ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NGS DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NGS DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NGS DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTEOMICS DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTEOMICS DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTEOMICS DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOCARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOCARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOCARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANODIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANODIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANODIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOPSY ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOPSY ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOPSY ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 20